Our results indicate, along with other preclinical models of PMD, that an early reactive glia response occurs following mutations in the PLP gene, which may represent a potentially clinically relevant, oligodendrocyte-independent therapeutic target for PMD. This evidence concerns the gene PLP1 and Pelizeaus-Merzbacher spectrum disorder.